Li Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
(138 intermediate revisions by the same user not shown)
Line 6: Line 6:
<div style="float:left;margin-left:0.3em;margin-right:0.7em">
<div style="float:left;margin-left:0.3em;margin-right:0.7em">


== '''Wei Li's Computational Epigenomics Lab''' ==  
== '''Computational Cancer Epigenomics and Transcriptomics (PI: Wei Li)''' ==  


[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
Line 15: Line 15:


==Recent News==
==Recent News==
. 06/2011A '''NIH R01 grant''' has been funded. We will work with Dr. Dent at MDA to understand USP22 Functions During Mammalian Development.
. 03/2015Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to '''PNAS'''.


. 06/2011Kaifu's epigenetic paper has been invited for revision in '''Molecular Cell'''.
. 01/2015Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to '''Cell Stem Cell''' -- the 100th paper we published.


. 05/2011Dr.Bert O'Malley's coregulator network paper has been published in '''Cell'''. Wei is a co-author on the paper.
. 01/2015Zheng's collaborative work on PRMT9 is accepted to '''Nature Communications'''.


. 04/2011Yuanxin's epigenomic paper has been invited for revision in '''Nature'''.
. 12/2014Zheng Xia is awarded a '''Keck fellowship''' in Computational Cancer Biology.


. 04/2011Liguo's Prostate Cancer RNA-seq paper has been officially accepted to  '''PNAS'''.
. 11/2014Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in '''Nature Communications'''.


. 03/2011Our Texas '''CPRIT Multi-Investigator grant''' has been funded with a total direct cost of ~$10M for 5 years. This project will bring together a "dream team" in cancer epigenetic research. We will direct the bioinformatics component for LONESTAR.  
. 09/2014Liguo's ChIP-exo methodology paper (MACE) is accepted to '''Nucleic Acids Research'''. MACE is recommended by Active Motif as the software solution for the company's new [https://www.activemotif.com/catalog/1050/chip-exo ChIP-exo kit and service].


. 01/2011Yuanxin's fragile nucleosome paper has been accepted to  '''Genome Research'''.
. 09/2014: Deqiang will start his tenure-track assistant professor position. Job well done.  


. 01/2011Yuanxin and Liguo's Atoh1 targetome paper has been accepted to '''PNAS'''.
. 09/2014Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to '''Molecular Cancer Research '''.  


. 12/2010Liguo's fly RNA-seq paper has been published in  '''Genome Research'''.
. 09/2014Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to '''Cell'''.


. 10/2010A Texas '''CPRIT grant''' has been funded. We will work with Dr. Goodell at BCM to understand DNA Methylgransferase 3B in normal and malignant hematopoiesis.  
. 08/2014:  '''Three Collaborative CPRIT grants''' are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.


. 08/2010Our '''Pilot Project''' has been funded by a NIH Stem Cell P01 Grant.  
. 08/2014Kaifu's "super promoter" paper is under review in '''Nature Genetics'''.  


. 07/2010The DNA methylation platform comparision paper has been accepted to '''Nature Biotechnology'''.
. 06/2014Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to '''Cell Stem Cell '''.  


. 06/2014:  Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to '''Molecular Cell '''.
. 02/2014:  Zheng's collaborative work on alternative splicing in heart development is accepted to '''Nature Communications'''.
. 02/2014:  Zheng's brain tumor 3'UTR regulator paper is accepted to '''Nature'''. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.
. 02/2014:  Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.
. 02/2014:  Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to '''Cell Stem Cell'''.
. 01/2014:  Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to '''Genome Biology'''.
. 01/2014:  Our collaborative work on Breast Cancer Epigenetics is accepted to '''Science Translational Medicine'''.
. 01/2014:  Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to '''Nature'''. This work links transcription elongation to tumor suppression.
. 12/2013: Kaifu's aging nucleosome paper is accepted to ''' Genes & Development'''
. 12/2013: We received a 5-year NIH/NHGRI '''R01''' grant (scored at 6 percentile in its first submission) to study DNA Methylation
. 11/2013: Wei will serve on the Editorial Board of '''Molecular Endocrinology'''
. 09/2013:  Deqiang's DNA methylation Canyon paper is accepted to '''Nature Genetics'''.
. 09/2013:  Xueqiu's bisulfite sequencing quality control paper (BSeQC) is accepted to '''Bioinformatics'''.
. 08/2013:  Kadir's p53 paper is accepted to '''Nucleic Acids Research'''
. 01/2013:  [http://www.bcm.edu/news/item.cfm?newsID=6723 BCM News] and  [http://epigenie.com/danpos-reveals-dynamic-nucleosomes Epigenie Headline] about our recent work on nucleosome dynamics.




[[Image:Banner.jpg‎‎]]
[[Image:Banner.jpg‎‎]]


[http://openwetware.org/wiki/Li_Lab:news News Archive]
[http://openwetware.org/wiki/Li_Lab:news News Archive]
Line 64: Line 92:
<div style="border-bottom: 1px dashed #9999CC;">
<div style="border-bottom: 1px dashed #9999CC;">


Our lab is focused on the design and application of bioinformatics algorithms to elucidate global regulatory mechanism by integrating data from ChIP-seq, DNA methylation, Nucleosome positioning, and RNA-seq. We are also working with bench and clinical collaborators to understand epigenetic gene regulation and transcription dynamics in various biological processes and disease models.  
Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have published more than 70 peer-reviewed papers through solid methodology development and extensive collaboration research, including 26 in Nature, Science and Cell series.
 
We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1900 citations since 2008.  
 
In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.
 
* '''Chromatin Factors''': ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..
 
* '''DNA Methylation''': DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.  


We have developed a number of widely used algorithms to detect and annotate genome-wide cis-regulatory regions, including a Hidden Markov Model ('''Bioinformatics''' 2005) and MAT ('''PNAS''' 2006) for analyzing ChIP-chip experiments on genome tiling arrays, CEAS ('''NAR''' 2006) for cis-regulatory element annotation, xMAN ('''BMC Genomics''' 2008) for microarray probe mapping, MACS ('''Genome Biology''' 2008) for model based analysis of ChIP-seq, BSMAP ('''BMC Bioinformatics''' 2009) for DNA methylation analysis using Bisulfite-seq, MMES ('''PLoS ONE''' 2010) for alternative splicing using RNA-seq, and fragile nucleosomes ('''Genome Re'''s 2011) using MNase-seq. These algorithms have gathered thousands of academic users worldwide and hundreds of citations, including > 30 papers in Cell and Nature series. We are currently working on bioinformatics development for 1) Transcription factor binding and histone modifications (ChIP-seq); 2) DNA methylation at single nucleotide resolution (Bisulfite-seq); 3) Nucleosome remodeling (Mnase-seq); 4) Alternative splicing (RNA-seq).
* '''Nucleosome Organization''': Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.


We have extensive experience in collaborative research, such as Estrogen Receptor regulation in breast cancer ('''Cell''' 2005; '''Nature Genetics''' 2006), Androgen Receptor regulation in prostate cancer ('''Molecular Cell''' 2007; '''Cell''' 2009), chromatin factor FoxA1 in epigenetic regulation ('''Cell''' 2008), Atoh1 in neuron development ('''PNAS''' 2011), fly transcriptome using RNA-seq ('''Genome Res''' 2011), and chimerical RNA biomarkers in prostate cancer ('''PNAS''' 2011). My laboratory also plays an important role in the BCM Epigenomics Data Analysis and Coordination Center for a five-year NIH Roadmap Epigenomics Program.
* '''Transcriptome''': chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


   
   

Revision as of 14:09, 27 March 2015

Home        People        Publications        Collaborations        Software        Positions        Contact       


Recent News

. 03/2015: Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to PNAS.

. 01/2015: Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to Cell Stem Cell -- the 100th paper we published.

. 01/2015: Zheng's collaborative work on PRMT9 is accepted to Nature Communications.

. 12/2014: Zheng Xia is awarded a Keck fellowship in Computational Cancer Biology.

. 11/2014: Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in Nature Communications.

. 09/2014: Liguo's ChIP-exo methodology paper (MACE) is accepted to Nucleic Acids Research. MACE is recommended by Active Motif as the software solution for the company's new ChIP-exo kit and service.

. 09/2014: Deqiang will start his tenure-track assistant professor position. Job well done.

. 09/2014: Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to Molecular Cancer Research .

. 09/2014: Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to Cell.

. 08/2014: Three Collaborative CPRIT grants are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.

. 08/2014: Kaifu's "super promoter" paper is under review in Nature Genetics.

. 06/2014: Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to Cell Stem Cell .

. 06/2014: Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to Molecular Cell .

. 02/2014: Zheng's collaborative work on alternative splicing in heart development is accepted to Nature Communications.

. 02/2014: Zheng's brain tumor 3'UTR regulator paper is accepted to Nature. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.

. 02/2014: Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.

. 02/2014: Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to Cell Stem Cell.

. 01/2014: Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to Genome Biology.

. 01/2014: Our collaborative work on Breast Cancer Epigenetics is accepted to Science Translational Medicine.

. 01/2014: Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to Nature. This work links transcription elongation to tumor suppression.

. 12/2013: Kaifu's aging nucleosome paper is accepted to Genes & Development

. 12/2013: We received a 5-year NIH/NHGRI R01 grant (scored at 6 percentile in its first submission) to study DNA Methylation

. 11/2013: Wei will serve on the Editorial Board of Molecular Endocrinology

. 09/2013: Deqiang's DNA methylation Canyon paper is accepted to Nature Genetics.

. 09/2013: Xueqiu's bisulfite sequencing quality control paper (BSeQC) is accepted to Bioinformatics.

. 08/2013: Kadir's p53 paper is accepted to Nucleic Acids Research

. 01/2013: BCM News and Epigenie Headline about our recent work on nucleosome dynamics.


News Archive




Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have published more than 70 peer-reviewed papers through solid methodology development and extensive collaboration research, including 26 in Nature, Science and Cell series.

We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1900 citations since 2008.

In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.

  • Chromatin Factors: ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..
  • DNA Methylation: DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.
  • Nucleosome Organization: Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.
  • Transcriptome: chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


Lab Intranet openwetware


<html> <script type="text/javascript">

 var _gaq = _gaq || [];
 _gaq.push(['_setAccount', 'UA-5924762-2']);
 _gaq.push(['_trackPageview']);
 (function() {
   var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
   ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
   var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
 })();

</script> </html>